On Friday, atai Life Sciences shared results from its Phase IIa trial with PCN-101, R-ketamine, for treatment-resistant depression.
Disappointingly, the study did not meet its primary endpoint of a statistically significant change in Montgomery-Åsberg Depression Rating Scale (MADRS) scores.
After the announcement, atai shares fell 40% in pre-market trading, and as of writing are down 33%.
READ MORE
Psychedelic-assisted therapies are increasingly being used in the treatment of eating disorders, such as anorexia.
Read More
If passed, the bill would amend New York state law to legalise the possession, use and cultivation of entheogens.
Read MoreMAPS announces positive results from Phase III MDMA trial.
Psilocybin-assisted therapy shows promise for binge eating disorder.
2023 inflection points in psychedelic healthcare.
Ketamine therapy and the rise of ketamine clinics.
The psychedelic renaissance in Australia.
The expansion of ketamine clinics across the US.
Filament Health and Jaguar form joint venture for botanical medicines.
Psyence to partner with iNGENū CRO for Australian clinical trial.
The efficacy of ketamine-assisted therapy for depression.
On Thursday, 6 July, industry leaders will converge at the iconic British Museum for PSYCH Symposium: London 2023.
Super Early Bird tickets on sale for £249 + VAT.
TICKET REGISTRATIONCanalisation and plasticity in psychopathology.
An overview of N,N-Dimethyltryptamine (DMT).
Psilocybin trials to treat opioid and methamphetamine use disorder.
Global ayahuasca survey highlights adverse effects.
Would your organisation benefit from engaging with Europe’s psychedelic medicine community?
Event partnership provides the opportunity to engage with an audience ready to support the development of psychedelic healthcare.
Previous partners include COMPASS Pathways, Beckley Psytech and Awakn Life Sciences.
PARTNERSHIP OPPORTUNITIESMissouri lawmaker amends psilocybin bill.
Patients pushing for psilocybin legalisation in Canada.
Movement to legalise psilocybin services in Utah.
Psilocybin services proposed in Virginia.
Do you know a spokesperson who could provide insights on the future of psychedelic healthcare?
Previous symposium speakers include:
Prince Harry turned to psychedelic healthcare to cope with grief.
Effect of breathwork on stress and mental health.
Long-term health problems hamper UK economy.
Students’ risk of mental health issues linked to subject they study.
In 2023, the psychedelic healthcare industry is expected to be worth US$1.2 billion.
With data cited by The Economist, The Psychedelics as Medicine Report provides market intelligence and exclusive insights.
COMPLIMENTARY DOWNLOAD